Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)
GPCR · MARKET VIEW
Market view · as of Jun 15, 2026
Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.35 est · in line
52-wk position
34.5%
-54.2% vs 52w high · +7.8% 1mo
Price (last ~year)
Structure Therapeutics recently reported positive Phase 2 results for its oral GLP-1 candidate aleniglipron, with plans to initiate Phase 3 trials in the third quarter of 2026. The clinical-stage company remains pre-revenue, reporting a $76.2 million net loss for the first quarter of 2026 and holding $316.2 million in cash against $5.8 million in debt. Shares closed at $42.93 with a market capitalization of $3.05 billion, following recent analyst price target adjustments.
Valuation
- Market cap
- $3.05B
- P/B
- 2.108
- EV/EBITDA
- -13.46
- Beta
- -1.423
- Analyst target
- $104.59
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -11.9%
- ROA
- -9.4%
Price movement
- Last
- $42.93
- 1-month
- +7.8%
- 3-month
- -17.3%
- RSI (14)
- 64
- vs SMA200
- -10.0%
- 52-wk position
- 34.5% -54.2% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $0 | $-89.6M | $-76.2M | $-74.8M |
| 2025-12-31 | $0 | $24.0M | $33.0M | $33.6M |
| 2025-09-30 | $0 | $-73.8M | $-65.7M | $-65.3M |
| 2025-06-30 | $0 | $-70.5M | $-61.7M | $-61.2M |
Recent news
- Bearish Structure Therapeutics Price Target Cut to $70.00/Share From $100.00 by HC Wainwright & Co. · 2026-06-12
- Somewhat-Bearish H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com · 2026-06-11
- Bullish J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating · 2026-06-10
- Bullish Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $101 · 2026-06-08
- Neutral Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron · 2026-06-07
- Bullish Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron · 2026-06-07
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)